Charles Schwab’s Mural Oncology MURA Stock Holding History

Charles Schwab’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-65,082	Closed	-$318K	–	3659
2024 Q1	$318K	Sell	65,082 -16,126	-20%	-$78.3K	﹤0.01%	3164
2023 Q4	$481K	Buy	+81,208	New	+$327K	﹤0.01%	3088

Other funds holding MURA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's MURA Position: Q2 2024 in Review

Charles Schwab sold out of Mural Oncology (MURA) in Q2 2024, closing a stake of 65,082 shares — an estimated $318K sold.

Charles Schwab first reported a position in MURA in Q4 2023 and held it in 2 quarters. The position peaked at $481K in Q4 2023. 86 funds tracked by Wall St. Rank hold MURA as of Q2 2024.

Charles Schwab reported no remaining Mural Oncology position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 65,082 Mural Oncology shares in Q2 2024, an estimated $318K.
Charles Schwab first reported a position in Mural Oncology in Q4 2023 and held it in 2 quarters.
Charles Schwab's Mural Oncology position peaked at $481K in Q4 2023.
86 funds tracked by Wall St. Rank held Mural Oncology as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.